IRRAS Announces Release of Clinical Data that Validates Safety and Effectiveness of IRRAflow System in Treating Chronic Subdural Hematomas
· Length of hospitalization reduced by more than 50% versus US national average · No complications or recurrence of bleeding seen during patient treatments at University of California IrvineStockholm, September 29, 2020 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the presentation of clinical research at the 18th Annual Meeting of the Neurocritical Care Society (NCS) that showed that the company’s IRRAflow system safely treats chronic subdural hematomas while also